StemRIM Inc. AI Stock Analysis
Want to see JP:4599 full AI Analyst Report?
StemRIM Inc. (4599) AI Stock Analysis
StemRIM Inc.
(TSE/TYO:4599)
The score is held down primarily by weak financial performance (zero revenue and ongoing losses with sustained cash burn) and bearish technicals (price far below key moving averages with negative momentum). A low-debt balance sheet provides some stability, but declining equity/assets and negative earnings limit valuation support.
StemRIM Inc. (4599) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 7.58B
- Dividend Yield
- ―
- Average Volume (3M)
- 533.88K
- Price to Earnings (P/E)
- -4.0
- Beta (1Y)
- 1.28
- Revenue Growth
- ―
- EPS Growth
- 4.85%
- Country
- Japan
- Employees
- 48
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
StemRIM Inc. Business Overview & Revenue Model
Company Description
StemRIM is a biotechnology firm dedicated to developing regenerative medicines aimed at treating severe and challenging diseases. Its product pipeline includes PJ1, a regeneration-inducing medicine based on HMGB1 peptides, which is currently undergoi...
StemRIM Inc. Financial Statement Overview
Summary
Overall financials are weak: income statement performance has deteriorated sharply with revenue falling to zero in 2024–2026 and sizable losses persisting, while cash flow shows sustained operating and free cash flow burn. The balance sheet is a relative positive due to essentially no debt, but equity and assets are trending down, reflecting losses consuming capital.
Income Statement
18Very NegativeBalance Sheet
64PositiveCash Flow
24Negative| Breakdown | TTM | Jul 2026 | Jul 2025 | Jul 2024 | Jul 2023 | Jul 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 2.35B | 22.98M |
| Gross Profit | -38.36M | -38.36M | -49.50M | -44.35M | 2.30B | 22.98M |
| EBITDA | -1.96B | -1.96B | -1.92B | -2.03B | 190.18M | -1.93B |
| Net Income | -1.85B | -1.85B | -1.93B | -2.02B | 168.35M | -1.95B |
Balance Sheet | ||||||
| Total Assets | 5.91B | 5.91B | 7.52B | 9.09B | 10.72B | 9.61B |
| Cash, Cash Equivalents and Short-Term Investments | 5.38B | 5.38B | 6.99B | 8.41B | 10.22B | 8.88B |
| Total Debt | 0 | 0 | 0 | 0 | 531.00K | 3.67M |
| Total Liabilities | 196.04M | 196.04M | 210.27M | 194.06M | 348.51M | 207.74M |
| Stockholders Equity | 5.71B | 5.71B | 7.31B | 8.89B | 10.37B | 9.40B |
Cash Flow | ||||||
| Free Cash Flow | 0 | -1.62B | -1.46B | -1.88B | 1.14B | -1.40B |
| Operating Cash Flow | 0 | -1.61B | -1.41B | -1.88B | 1.14B | -1.40B |
| Investing Cash Flow | 0 | -3.21B | -42.50M | -4.78M | -344.00K | -330.00K |
| Financing Cash Flow | 0 | 0 | 41.25M | 78.97M | 202.60M | 112.86M |
StemRIM Inc. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4599, the sentiment is Negative. The current price of 119.00 is below the 20-day moving average (MA) of 140.65, below the 50-day MA of 191.98, and below the 200-day MA of 275.24, indicating a bearish trend. The MACD of -19.69 indicates Negative momentum. The RSI at 24.46 is Positive, neither overbought nor oversold. The STOCH value of 20.93 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4599.
StemRIM Inc. Peers Comparison
Overall Rating
JP:459349Neutral
JP:488049Neutral
JP:497843Neutral
JP:777442Neutral- JP:459942Neutral
JP:777626Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| JP:4593 | 49Neutral | JPY 32.26B | 48.59 | ― | ― | -47.32% | ― |
| JP:4880 | 49Neutral | JPY 5.68B | 57.34 | ― | 1.75% | -9.94% | ― |
| JP:4978 | 43Neutral | JPY 11.97B | -24.40 | ― | ― | -18.71% | -246.54% |
| JP:7774 | 42Neutral | JPY 27.45B | -75.71 | ― | ― | 17.05% | 10.47% |
| JP:4599 | 42Neutral | JPY 7.46B | -4.04 | ― | ― | ― | 4.85% |
| JP:7776 | 26Underperform | JPY 6.90B | -5.90 | ― | ― | -56.16% | 3.12% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:4599 | StemRIM Inc. | 119.00 | -168.00 | -58.54% | |
| JP:4593 | Healios KK | 241.00 | -220.00 | -47.72% | |
| JP:4880 | CellSource Co., Ltd. | 281.00 | -227.00 | -44.69% | |
| JP:4978 | ReproCELL Inc. | 115.00 | -53.00 | -31.55% | |
| JP:7774 | Japan Tissue Engineering Co., Ltd. | 680.00 | 185.00 | 37.37% | |
| JP:7776 | CellSeed Inc. | 171.00 | -261.00 | -60.42% |
StemRIM Inc. Corporate Events
StemRIM Wins U.S. Patent for Stem Cell Gene Therapy Targeting Rare Skin Disease
StemRIM Inc. has secured a U.S. patent for a stem cell gene therapy technology, development code SR-GT1, designed as a curative treatment for recessive dystrophic epidermolysis bullosa. The invention covers the therapeutic use of autologous mesenchym...
StemRIM Plans Zero-Cost Stock Options to Align Talent With Long-Term Growth
StemRIM Inc. has proposed issuing up to 8,000 stock options, in the form of new share subscription rights, free of charge to executive officers, employees, and approved external collaborators, subject to shareholder approval at its October 20th annua...
StemRIM Strengthens Governance Ahead of Growth Drive
StemRIM Inc. has nominated a slate of five directors, including one new outside director, to be approved at its October 28, 2026 annual shareholders meeting, as the terms of all current directors expire. The proposed expansion of the board by one sea...
StemRIM Secures South Korean Patent for Redasemtide in Cartilage Disorders
StemRIM Inc., a biotech venture from The University of Osaka, is developing drug-based regenerative therapies that activate the body’s own mesenchymal stem cells to repair damaged tissues rather than relying on cell transplantation. Its flagship cand...
StemRIM Grants New Stock Options to Directors as Regenerative Medicine Pipeline Advances
StemRIM Inc. has set final terms for its 20th series of stock acquisition rights, issuing 3,000 stock option units to four directors, representing rights to acquire 300,000 common shares at an exercise price of 24,500 yen per unit. The move underscor...
StemRIM Sets Terms for New Employee Stock Option Issuance
StemRIM Inc. has approved detailed terms for its 19th series of stock acquisition rights to be granted as stock options to employees, issuing 4,989 units corresponding to 498,900 common shares. The options, allocated to 47 employees at an exercise pr...
StemRIM Deepens Losses but Secures Funding for Regenerative Medicine Push
StemRIM Inc. reported another year of operating losses for the fiscal year ended July 31, 2026, with net income remaining in the red and equity per share declining as total assets and net assets fell. Cash and cash equivalents dropped sharply as oper...
StemRIM Issues New Director Stock Options With Limited Dilution
StemRIM Inc. has approved the issuance of its 20th series of stock acquisition rights as stock options to directors, under a previously sanctioned remuneration framework that caps annual stock option value for directors and corporate auditors. The op...
StemRIM Issues New Employee Stock Options With Limited Dilution Impact
StemRIM Inc. has approved the issuance of its 19th series of stock acquisition rights as stock options to employees, with up to 4,989 units convertible into 498,900 shares of common stock. The options, issued without payment and exercisable between 2...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 05, 2026